Claims for Patent: 9,200,283

Summary for Patent: 9,200,283

Title:	Methods for the treatment of hepatitis B and hepatitis D infections
Abstract:	It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.
Inventor(s):	Bazinet; Michel (Montreal, CA), Vaillant; Andrew (Roxboro, CA)
Assignee:
Application Number:	14/449,173
Patent Claims:	1. A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment (a) a siRNA that targets mRNA of the HBV genome encoding the hepatitis B surface antigen (HBsAg) and catalyzes degradation of that mRNA, and (b) at least one pharmaceutically acceptable agent selected from the group consisting of: thymosin .alpha.1; interferon .beta.-1a; interferon .beta.-1 b; interferon .gamma.-1b; interferon .lamda.1; interferon .lamda.2; interferon .lamda.3; pegylated interferon .alpha.-2a; pegylated interferon .alpha.-2b; pegylated interferon .lamda.1; pegylated interferon .lamda.2 GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7- -dihydropteridin-6-one); dehydroepiandrosterone; androstenediol; and androstenetriol. 2. A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an siRNA chelate complex formulation comprising a siRNA catalyzing the degradation of a mRNA used to produce the hepatitis B surface antigen (HBsAg) protein and at least one a pharmaceutically acceptable agent selected from the group consisting of: thymosin .alpha.1; interferon .alpha.-2a; interferon .alpha.-2b; interferon .alpha.-N3; interferon .beta.-1a; interferon .beta.-1b; interferon .gamma.-1b; interferon .lamda.1; interferon .lamda.2; interferon .lamda.3; pegylated interferon .alpha.-2a; pegylated interferon .alpha.-2b; pegylated interferon .lamda.1; pegylated interferon .lamda.2 GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydro- pteridin-6-one); dehydroepiandrosterone; androstenediol; and androstenetriol. 3. The method of claim 1 or 2, wherein said siRNA and said pharmaceutically acceptable agent are formulated within the same pharmaceutical composition. 4. The method of claim 1 or 2, where said siRNA and said pharmaceutically acceptable agent are formulated within separate pharmaceutical compositions. 5. The method of claim 1 or 2, wherein said siRNA and said pharmaceutically acceptable agent are administered simultaneously. 6. The method of claim 1 or 2, wherein said siRNA and said pharmaceutically acceptable agent are administered by a different route of administration. 7. The method of claim 1 or 2, wherein said siRNA and said pharmaceutically acceptable agent are administered using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intramuscular injection, intravenous injection and intravenous infusion. 8. The method of claim 1 or 2, which further comprises administering at least one second pharmaceutically acceptable agent selected from the group consisting of: tenofovir disoproxil fumarate; entecavir; telbuvidine; adefovir dipivoxil; and lamivudine.

Details for Patent 9,200,283

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2032-08-30
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2032-08-30
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2032-08-30